110 citations
,
August 2015 in “Neuropsychopharmacology” High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
April 2010 in “Nature Reviews Urology”
11 citations
,
September 2012 in “Journal of obstetrics and gynaecology Canada” Testosterone therapy seems safe for short-term use in postmenopausal women with low sexual desire, but more research on long-term effects is needed.
15 citations
,
August 2016 in “Current Urology Reports” Nandrolone and oxandrolone could help treat male health issues like muscle loss and low testosterone.
4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.
5 citations
,
August 2012 in “Journal of Dermatology” Tamoxifen may cause female hair loss by increasing androgen receptor expression.
11 citations
,
July 2020 in “Scientific Reports” Statins may be linked to reproductive organ conditions, and their risks should be monitored.
September 2025 in “International Journal of Women’s Dermatology” Oral spironolactone effectively promotes hair growth in premenopausal women but may cause irregular menstruation.
8 citations
,
February 2009 in “Current Women's Health Reviews” Testosterone treatment can improve sexual function and bone density in women but may have adverse effects and requires more research on safety and guidelines.
A mix of Polygonatum sibiricum and Nelumbinis semen may ease menopause symptoms with fewer side effects.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” January 2026 in “Journal of Education Health and Sport” Letrozole with lifestyle changes improves fertility in women with PCOS.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
4 citations
,
January 2015 in “Pharmacology” Serenoa repens may cause early puberty and should be used cautiously in children.
June 2023 in “Sri Lanka Journal of Menopause” April 2025 in “Frontiers in Pharmacology” Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
5 citations
,
November 2015 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.
March 2026 in “Inflammopharmacology” Ursolic acid from Ochrosia elliptica leaves may help manage PCOS symptoms.
June 2016 in “Indian Journal of Pharmacy Practice” Stopping fluvoxamine can reverse hair loss caused by the drug.
42 citations
,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
39 citations
,
August 2022 in “Pharmaceutics” Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
14 citations
,
May 2005 in “Steroids” A new method was developed to make finasteride for treating hair loss.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
January 2025 in “JAAD International” Bicalutamide added no extra benefit over minoxidil alone for female-pattern hair loss.
1 citations
,
January 2013 in “UNICA IRIS Institutional Research Information System (University of Cagliari)” Hormonal contraceptives may reduce social behavior and sexual motivation by lowering allopregnanolone levels.
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
2 citations
,
January 2013 in “Iraqi journal of Medical Sciences” 4 citations
,
January 2018 in “JBRA assisted reproduction” Orlistat helped reduce weight and testosterone in obese women with PCOS but did not significantly affect other androgens or cholesterol levels.
1 citations
,
March 1997 in “Journal of Chromatography B: Biomedical Sciences and Applications” Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.